Eiger BioPharmaceuticals updates progress in development of exendin 9-3
Eiger BioPharmaceuticals announced an update on the company's development program for exendin 9-39 as a potential treatment for post-bariatric hypoglycemia, a rare, debilitating and chronic disorder with no approved treatment. Eiger is developing a novel subcutaneously-administered form of exendin 9-39 for patients who experience dangerously low post-prandial (post-meal) blood glucose levels due to PBH. Eiger has now filed an investigational new drug application for exendin 9-39 with the FDA. Eiger is the exclusive licensee of exendin 9-39 from Stanford University, which, under the Stanford IND, has generated and presented promising proof of concept data in multiple studies in patients with PBH, including an intravenous infusion study of exendin 9-39 and a subcutaneous injection study involving single-ascending doses of exendin 9-39. Eiger is currently sponsoring a multiple-ascending dose study involving SC exendin 9-39 in patients with PBH at Stanford, with interim data to be presented at a company-hosted Analyst / Key Opinion Leader event on December 9th.